Complications of cirrhosis. III. Hepatic encephalopathy

Journal of Hepatology

Volumn 32, Issue SUPPL.1, 2000, Pages 171-180

  Butterworth, Roger F ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Ammonia; Chronic liver failure; Cirrhosis; Hepatic encephalopathy; Magnetic resonance imaging; Manganese; Monoamine oxidase; Nitric oxide synthase; Peripheral type benzodiazepine receptors; Portal systemic encephalopathy; Positron emission tomography; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMMONIA; BENZODIAZEPINE RECEPTOR; BENZOIC ACID; FLUMAZENIL; GLUTAMINE; LACTULOSE; MANGANESE; NEOMYCIN; NITRIC OXIDE SYNTHASE; ORNITHINE ASPARTATE;

ANIMAL TISSUE; ASTROCYTOSIS; BRAIN PERFUSION; CLINICAL ARTICLE; COMA; CONTROLLED STUDY; FLAPPING TREMOR; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FAILURE; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTOSYSTEMIC ANASTOMOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN RESTRICTION; RAT; REVIEW; SLEEP DISORDER; STUPOR;

ANIMALS; BRAIN; CHRONIC DISEASE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; NEUROTOXINS; NEUROTRANSMITTER AGENTS;

EID: 0034005901     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(00)80424-9     Document Type: Article

References (83)

1. Quero JC, Schalm SW Subclinical hepatic encephalopathy. Semin Liver Dis 1996; 16: 321-8.
2. Tarter RE, Hegedus AM, van Thiel DH, Schade RR, Gavaler JS, Starzl TE. Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. Gastroenterology 1984; 86: 1421-7.
3. Pomier Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis 1996; 16: 315-20.
4. Somberg KA, Riegler JL, Laberge JM, Doherty-Simor MM, Bachetti P, Roberts JP, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90: 549-55.
5. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study. Hepatology 1994; 20: 46-55.
6. Dagenais M, Pomier Layrargues G, Dufresne MP, Roy A, Fenyves D, Lapointe R. Experience with the transjugular intrahepatic portacaval shunt. Ann Chir 1994; 48: 671-8.
7. Coldwell DM, Ring EJ, Rees CR, Zemel G, Darcy MD, Haskal ZJ, et al. Multicenter investigation of the role of transjugular intrahepatic portosystemic shunt in management of portal hypertension. Radiology 1995; 196: 335-40.
8. Rössle MR, Haag K, Ochs A, Sellinger M, Noldge G, Perarneau JM, Berger E, et al. The transjugular intraheptic portosystemic stent-shunt procedures for variceal bleeding. N Engl J Med 1994; 330: 165-71.
9. Martin M, Zajko AB, Orons PD, Dodd G, Wright H, Colangelo J, et al. Transjugular intrahepatic portosystemic stent shunting for control of acute and recurrent upper gastro-intestinal haemorrhage related to portal hypertension. Gut 1993; 34: 968-73.
10. Ochs A, Rössle M, Haag K, Hauenstein KH, Deibert P Siegerstetter V, et al. The transjugular intrahepatic portosystemic stentshunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-7.
11. Jalan RJ, Elton RA, Rcdhcard DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal hemorrhage. J Hepatol 1995; 23: 123-8.
12. Audet R, Butterworth RF. Portacaval anastomosis results in more severe neurological impairment and more widespread reductions in cerebral metabolism in old versus young adult rats: implications for post-TIPS encephalopathy. Metab Brain Dis 1998; 13: 69-78.
13. Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996; 16: 245-53.
14. Butterworth RF, Giguère J, Michaud J, Lavoie J, Pomier Layrargues G. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12.
15. Lockwood AH, Weissenborn K, Butterworth RF. An image of the brain in patients with liver disease. Curr Opin Neurol 1997; 10: 525-33.
16. Weissenborn K, Ehrenheim CH, Hori A, Kubicka S, Manns MP. Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metab Brain Dis 1995; 10: 219-31.
17. Taylor-Robinson SD, Oatridge A, Hajnal JV, Burroughs AK, McIntyre N, deSouza NM. MR Imaging of the basal ganglia in chronic liver disease: Correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatrie status. Metab Brain Dis 1995; 10: 175-88.
18. Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Millette PC, et al. Increased blood manganese in cirrhotic patients: relationship with magnetic resonance images and neurological symptoms. Hepatology 1996; 24: 1116-20.
19. 1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993; 43: 65-9.
20. Devenyi AG, Barron TF, Mamourian AC. Dystonia, hyperintense basal ganglia, and high whole blood manganese levels in Alagille's syndrome. Gastroenterology 1994; 106: 1068-71.
21. 1-weighted MR images in patients receiving parenteral nutrition. Radiology 1991; 191: 117-20.
22. Pomier Layrargues G, Spahr L, Butterworth RF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 1995; 345: 735.
23. Butterworth RF, Spahr L, Fontaine S, Pomier Layrargues G. Manganese toxicity, dopaminergic dysfuncion and hepatic encephalopathy. Metab Brain Dis 1995; 4: 259-67.
24. Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117: 640-4.
25. Taylor-Robinson SD, Sargentoni J, Marcus CD, Morgan MY, Bryant DJ. Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. Metab Brain Dis 1994; 9: 347-59.
26. Laubenberger J, Haussinger D, Boyer S, Guffer H, Henning J, Lange M. Proton magnetic resonance spectroscopy of brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997; 112: 1610-6.
27. Morgan MY. Noninvasive neuroinvestigation in liver disease. Semin Liver Dis 1996; 16: 293-314.
28. Taylor-Robinson SD, Sargentoni J, Mallalieu RJ, Bell JD, Bryant DJ, Coutts GA, et al. Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology 1994; 20: 1173-8.
29. 1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra. Metab Brain Dis 1996; 11: 249-68.
30. Lockwood AH, Murphy BW, Donnelly KZ, Mahl TC, Perini S. Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 1993; 18: 1061-8.
31. Lockwood AH, Yap EWH, Rhoades HM, Wong W. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 1991a; 11: 331-6.
32. O'Carroll RE, Hayes PC, Ebmeier KP, Dougall N, Murray C, Best JJK, et al. Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 1991; 337: 1250-3.
33. Lockwood AH, Yap EWH, Wong W-H. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991b; 11: 337-41.
34. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroent 1997; 92: 1429-39.
35. Gabuzda D Jr, Philips GB, Davidson CS. Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. N Engl J Med 1952; 246: 124-30.
36. Szerb JC, Butterworth RF. Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog Neurobiol 1992; 39: 135-53.
37. Lai JCK, Cooper AJL. α-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution and effects of inhibitors. J Neurochem 1986; 47: 1376-86.
38. Hindfelt B, Plum F, Duffy TE. Effects of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977; 59: 386-96.
39. Yao H, Sadoshima S, Fujii K, Kusada K, Ishitsuka T, Tamaki K, et al. Cerebrospinal fluid lactate in patients with hepatic encephalopathy. Eur Neurol 1987; 27: 182-7.
40. Therrien G, Giguère JF, Butterworth RF. Increased cerebrospinal fluid lactate reflects deterioration of neurological status in experimental portal-systemic encephalopathy. Metab Brain Dis 1991; 6: 225-31.
41. 3H]arginine uptake in brain following portacaval anastomosis. J Neurochem 1995; 65: 677-81.
42. Bender AS, Norenberg MD. Effect of ammonia on L-glutamate uptake in cultured astrocytes. Neurochem Res 1996; 21: 567-73.
43. Knecht K, Michalak A, Rose C, Rothstein JD, Butterworth RF. Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci Lett 1997; 229: 201-3.
44. Hazell AS, Desjardins P, Butterworth RF. Exposure of primary astrocyte cultures to manganese results in increased binding sites for "peripheral-type" benzodiazepine receptor ligands. Neurosci Lett 1999 271: 5-8.
45. Hazell AS, Desjardins P, Butterworth RF. Increased expression of glyceraldehyde-3-phosphate dehydrogenase in cultured astrocytes following exposure to manganese. Neurochem Int 1999; 35: 11-7.
46. Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: A possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Mcd 1974; 83: 16-28.
47. Zieve L. Role of toxins and synergism in hepatic encephalopathy. In: Butterworth RF, Pomier Layrargues, editors. Hepatic Encephalopathy: Pathophysiology and Treatment. New Jersey: Humana Press; 1989. p. 141-56.
48. Mousseau DD, Baker GB, Butterworth RF. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J Neurochem 1997; 68: 1200-8.
49. Bergeron M, Reader TA, Pomier Layrargues G, Butterworth RF. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 1989; 14: 853-9.
50. Young SN, Lai S. CNS tryptamine metabolism in hepatic coma. J Neural Transm 1980; 47: 153-61.
51. Bergeron M, Swain MS, Reader TA, Butterworth RF. Regional alterations of dopamine and its metabolites in rat brain following portacaval anastomosis. Neurochem Res 1995; 20: 79-86.
52. Bergeron M, Swain MS, Reader TA, Grondin L, Butterworth RF. Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval-shunted rat. J Neurochem 1990; 55: 222-9.
53. Desjardins P, Bandeira P, Raghavendra Rao VL, Ledoux S, Butterworth RF. Increased expression of the peripheral-type benzodiazepine rcccptor-isoquinoline carboxamide binding protein mRNA brain following portacaval anastomosis. Brain Res 1997; 758: 255-8.
54. 3H-PK 11195 in rat brain following portacaval anastomosis. Brain Res 1992; 585: 295-8.
55. 3H]PK 11195 in rats following portacaval anastomosis. Dig Dis Sci 1994; 39: 1055-63.
56. Lavoie J, Pomier Layrargues G, Butterworth RF. Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 1990; 11: 874-8.
57. 3H]-PK 11195 in congenital ornithine transcarbamylase deficient sparse-fur mouse. Pediat Res 1993; 34: 777-80.
58. 3H]PK 11195. Neurosci Lett 1994; 177: 35-8.
59. Raghavendra Rao VL, Audet RM, Butterworth RF. Increased neuronal nitric oxide synthase expression in brain following portacaval anastomosis. Brain Res 1997; 765: 169-72.
60. 3H-nitroarginine into rat brain synaptosomes. J Neurochem 1997; 68: 337-43.
61. Raghavendra Rao VL, Butterworth RF. Neuronal nitric oxide synthase and hepatic encephalopathy. Metab Brain Dis 1998; 12: 175-89.
62. 2 receptor density in hepatic encephalopathy. Neurosci Lett 1993; 162: 192-6.
63. Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis. Gastroenterology 1961; 40: 389-96.
64. Salomon F, Beaubernard C, Thangapregassam MJ, Grange D, Bismuth H. Encéphalopathie hépatique expérimentale. II Étude de la réaction à la douleur chez le rat avec anastomose portocave. Biol Gastroenterol 1976; 9: 105-8.
65. Thorton JR, Losowksy MS. Plasma methionine enkephalin concentration and prognosis in primary biliary cirrhosis. Br Med J 1988; 297: 1241-2.
66. Panerai AE, Salerno F, Baldissera F, Martini A, Di Giulio AM, Mantegazza P. Brain β-endorphin concentrations in experimental chronic liver disease. Brain Res 1982; 247: 188-90.
67. Routtenberg A. Self-stimulation pathways: origins and terminations - a three stage technique. In: Wauquier A, Rolls BJ, editors. Brain-Stimulation Reward. Amsterdam: Elsevier, North Holland Biochemical Press; 1976. p. 39.
68. Martin JR, Porchet H, Buhler R, Bircher J. Increased ethanol consumption and blood ethanol levels in rats with portacaval shunts. Am J Physiol 1985; 248: G287-92.
69. De Waele JP, Audet RM, Rose C, Butterworth RF. The portacaval-shunted rat: a new model for the study of the mechanisms controlling voluntary ethanol consumption and ethanol dependence. Alcohol Clin Exp Res 1997; 21: 305-10.
70. De Waele JP, Audet RM, Leong DK, Butterworth RF. Portacaval anastomosis results in region-selective changes of β-endorphin content and of μ and δ opiod receptor densities in rat brain. Hepatology 1996; 24: 895-901.
71. Ferenci P, Herneth A, Steindl P. Newer aproaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996; 16: 329-38.
72. Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon: Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med 1970; 283: 159-64.
73. Brown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut 1974; 15: 999-1004.
74. Lockwood AM, McDonald JM, Rieman RE. The dynamics of ammonia metabolism in men: Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-60.
75. Swart GR, van den Berg JWO, van Vuure JK, et al. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin Nutr 1989; 8: 329-36.
76. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-60.
77. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, et al. Orthinine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13: 147-57.
78. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992; 16: 138-44.
79. Pomier Layrargues G, Giguère JF, Lavoie J, Perney P, Gagnon S, D'Amour M, et al. Clinical efficacy of benzodiazepine antagonist RO 15-1788 (flumazenil) in cirrhotic patients with hepatic coma: results of a randomized double-blind placebo-controlled cross-over trial. Hepatology 1994; 19: 32-7.
80. Gyr K, Meier R, Haussler J, Bouletreau P, Fleig WE, Gatta A, Holstege A, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: A double blind, randomised, placebo controlled multicentre study. Gut 1996; 39: 319-24.
81. Butterworth RF, Wells J, Pomier Layrargues G. Detection of benzodiazepines in hepatic encephalopathy: Reply. Hepatology 1995; 2: 605.
82. Morgan MY, Jakobovits AW, James IM, Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980; 78: 663-70.
83. Uribe M, Farca A, Marquez MA, Garcia-Ramos G, Guevara L. Treatment of chronic portal systemic encephalopathy with bromocriptine: A double-blind controlled trial. Gastroenterology 1979; 76: 1347-51.